The expression of miRNA-29b is downregulated in CML patients, which is explained by its ability to silence several oncogenes, such as antiapoptotic myeloid cell leukemia sequence 1 (MCL-1) and p53 inhibitors [153]. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.